Age-related macular degeneration (AMD) and retinitis pigmentosa are leading causes of progressive vision loss worldwide. Both conditions share a common feature: dysfunction or degeneration of photoreceptor cells in the retina. While conventional therapies focus on slowing disease progression, peptide bioregulators offer a complementary approach by targeting cellular renewal at the source.
Visoluten is a Khavinson-lineage retinal peptide derived from young calf retinal tissue. In published Russian and Eastern-European research, Visoluten has been shown to support photoreceptor cell function, modulate gene expression in retinal pigment epithelium and improve dark adaptation in clinical observation studies of AMD patients.
The mechanism is rooted in the bioregulator hypothesis developed by Professor Vladimir Khavinson over 40 years of research. Short peptide signals enter cells, bind directly to specific gene promoter regions and restore physiological protein synthesis in tissue-matched cells. For the eye, this means supporting the photoreceptor renewal cycle that naturally declines with age and disease.
A typical protocol pairs Visoluten capsules with neuro-protective peptides like Pinealon and Cerluten to support the retinal-brain axis. Most clinical observers recommend 20-day cycles repeated 2–4 times per year. Improvements in subjective vision quality, contrast sensitivity and reduced glare are commonly reported.
Peptide bioregulators are not a replacement for ophthalmic care or anti-VEGF injections in wet AMD. They are a complementary tool — best used alongside an ophthalmologist-supervised treatment plan, lifestyle adjustments (UV protection, leafy greens, omega-3) and regular OCT monitoring.
